In the BioHarmony Drug Report Database

"Preview" Icon

Cladribine

Leustatin, Mavenclad, Litak (cladribine) is a small molecule pharmaceutical. Cladribine was first approved as Leustatin on 1993-02-26. It is used to treat b-cell chronic lymphocytic leukemia, hairy cell leukemia, multiple sclerosis, and non-hodgkin lymphoma in the USA. It has been approved in Europe to treat hairy cell leukemia and multiple sclerosis. Cladribine’s patents are valid until 2026-10-16 (FDA).

 

Trade Name

 

Litak, Mavenclad
 

Common Name

 

cladribine
 

ChEMBL ID

 

CHEMBL1619
 

Indication

 

b-cell chronic lymphocytic leukemia, hairy cell leukemia, multiple sclerosis, non-hodgkin lymphoma
 

Drug Class

 

Ribofuranil derivatives (pyrazofurin type)

Image (chem structure or protein)

Cladribine structure rendering